1. On Demand PrEP for Men at High Risk for HIV IPERGAY

2. On Demand PrEP for Men at High Risk for HIV IPERGAY: Study Design
Study Design: IPERGAY Study
Background: Randomized, phase 3, double-blind, placebo-controlled trial conducted in France and Canada that investigated tenofovir DF-emtricitabine as on-demand preexposure prophylaxis for men who sex with men or transgender women
Inclusion Criteria (400 enrolled) years of age or older and HIV seronegative - Men or TG women who have sex with men - Unprotected anal sex ≥2 partners in prior 6 months - Excluded if chronic HCV or HBsAg-positive - Excluded: CrCl <60 mL/min, glycosuria, proteinuria
Treatment Arms: - Placebo: (on demand schedule*) - Tenofovir DF-emtricitabine: (on demand schedule*)
Placebo
(n = 201)
Tenofovir DF-Emtricitabine
(n = 199)
On demand Schedule: take loading dose of two pills of TDF-FTC or placebo with food 2 to 24 hours before sex, followed by a third pill 24 hours after the first pill and a fourth pill 24 hours later. With multiple consecutive episodes of sex, take one pill per day until until 48 hours after last sex.
Source: Molina JM, et al. N Engl J Med. 2015;373:

3. On Demand PrEP for Men at High Risk for HIV IPERGAY: Design
IPERGAY On Demand Dosing Schedule
HIV Exposure Event
Time
2 tabs 2-24 hours before sex (or 1 pill if most recent dose taken <7 days prior)
1 tab 24 and 48 hours after the last pre-sex dose
Source: Molina JM, et al. N Engl J Med. 2015;373:

4. On Demand PrEP for Men at High Risk for HIV IPERGAY: Design
IPERGAY Dosing Schedule with Ongoing HIV Exposures
Ongoing HIV Exposures
Time
2 tabs 2-24 hours before sex (or 1 pill if most recent dose taken <7 days prior)
1 tab 24 and 48 hours after the last pre-sex dose
If sexual activity continues, then PrEP continues daily until 48 hours after last sex
*Otherwise, same process repeated with next exposure event
Source: Molina JM, et al. N Engl J Med. 2015;373:

5. On-Demand Preexposure Prophylaxis Event-Driven Strategy IPERGAY: Results
⇓ 86%
Additional data that could be added:
Median follow-up was 8.8 months (IQR: 4.3 to 20.5).
The average number of sexual partners participants had had in the previous two months was eight. Seventy per cent had had condomless anal sex in the previous two months.
The two participants in the Truvada arm who acquired HIV did not become infected until late in the study – one 16 and one 21 months after entering the study. Principal investigator Jean-Michel Molina said that the two had pretty certainly stopped taking PrEP by that time – they had even been returning unused pill bottles to the clinic.
During the study, 35% of participants were diagnosed with a sexually transmitted infection including 20% with gonorrhoea and 10% with syphilis; Jean-Michel Molina reported two in a hundred participants acquired hepatitis C, equating to six infections.
Pts used a median of 14 pills/month (IQR: 8-20).
Reference:
Molina J-M et al. On Demand PrEP With Oral TDF-FTC in MSM: Results of the ANRS Ipergay Trial Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, USA, abstract 23LB, 2015.
Due to high effectiveness of PrEP, participants unrandomized and all offered PrEP
Source: Molina JM, et al. N Engl J Med. 2015;373:

6. On-Demand Preexposure Prophylaxis Event-Driven Strategy IPERGAY: Conclusions
Conclusions: “The use of tenofovir DF-emtricitabine before and after sexual activity provided protection against HIV-1 infection in men who have sex with men. The treatment was associated with increased rates of gastrointestinal and renal adverse events.”
Source: Molina JM, et al. N Engl J Med. 2015;373: